Shire (SHPG) 8-K Other Events

EXHIBIT 99.01

Hampshire International Business Park Chineham  Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com
Press Release

Notification of major interests in shares

Basingstoke, UK and Philadelphia, US – May 28, 2008 – Shire Limited (LSE: SHP, NASDAQ: SHPGY)

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Shire Limited

2. Reason for the notification	State Yes/No
An acquisition or disposal of voting rights	Yes
An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An event changing the breakdown of voting rights
Other (please specify):  New Exemption DTR 5.1.3 (4) & DTR 5.1.5 (1)	Yes

3. Full name of person(s) subject to the notification obligation:	The Goldman Sachs Group Inc
4. Full name of shareholder(s) (if different from 3.):	Goldman, Sachs & Co., Goldman Sachs Financial Markets, L.L.C. Goldman Sachs Execution and Clearing, L.P
5. Date of the transaction (and date on which the threshold is crossed or reached if different):	23 May 2008
6. Date on which issuer notified:	27 May 2008
7. Threshold(s) that is/are crossed or reached:	3%
8. Notified details:

Registered in England 5492592  Registered Office as above

A: Voting rights attached to shares

Class/type of shares  if possible using the ISIN CODE	Situation previous to the Triggering transaction		Resulting situation after the triggering transaction
	Number of Shares	Number of Voting Rights	Number of shares	Number of voting rights		% of voting rights
			Direct	Direct	Indirect	Direct	Indirect
GB00B0KQX869 US82481R1068	14,131,540 14,203,341 (4,734,447 ADRs)	2.526% 2.539%		12,582 (4,194 ADRs)	115,000 17,101,950 (5,700,650 ADRs)	0.002%	0.021% 3.057%

B: Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument Expiration date Exercise/Conversion Period/ Date Number of voting rights that may be acquired if  the instrument is exercised/converted % of voting rights

Total (A+B)
Number of voting rights	% of voting rights
17,229,532	3.08%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

The interest in 115,000 shares arose from an interest held by Goldman, Sachs & Co., a wholly-owned  subsidiary of The Goldman Sachs Group Inc, acting as custodian for its customers. These shares are, or will be, registered in the name of Goldman Sachs Securities (Nominees), Limited.

The interest in 17,041,437 shares arose from an interest held by Goldman, Sachs & Co., a wholly-owned subsidiary of The Goldman Sachs Group Inc, acting as custodian for its customers of 5,680,479 American Depositary Receipts that are, or will be, held at the Depositary Trust Company of New York.

The interest in 60,513 shares arose from an interest held by Goldman, Sachs & Co., a wholly-owned subsidiary of The Goldman Sachs Group Inc, acting as discretionary manager of 20,171 American Depositary Receipts that are, or will be, held at the Depositary Trust Company of New York.

The interest in 11,502 shares arose from a beneficial interest held by Goldman Sachs Financial Markets L.L.C, a wholly owned indirect subsidiary of The Goldman Sachs Group Inc. of 3,834 American Depositary Receipts that are, or will be, held at the Depositary Trust Company of New York.

The interest in 1,080 shares arose from a beneficial interest held by Goldman Sachs Execution and Clearing LP, a wholly owned indirect subsidiary of The Goldman Sachs Group Inc. of 360 American Depositary Receipts that are, or will be, held at the Depositary Trust Company of New York.

Registered in England 5492592  Registered Office as above
 

Proxy Voting:

10. Name of the proxy holder:	N/A
11. Number of voting rights proxy holder will cease to hold:	N/A
12. Date on which proxy holder will cease to hold voting rights:	N/A

13. Additional information:	General Email Contact: shareholderdisclosures@gs.com
14. Contact name:	Sean Rogers/Alex Cox
15. Contact telephone number:	0207-552-9205 / 0207-774 -8774

Contact at Shire Limited: Tony Guthrie, Deputy Company Secretary, 01256 894754

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
	Eric Rojas (North America)	+1 484 595 8252

Notes to editors

SHIRE LIMITED

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.  Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in England 5492592  Registered Office as above